Mineralocorticoid receptor deletion in fibroblasts prevents diastolic dysfunction in preclinical models, indicating that MR antagonists benefit HFpEF by inhibiting fibroblast MR.
Does fibroblast-specific MR deletion prevent diastolic dysfunction in a preclinical mouse model of HFpEF?
Fibroblast-specific MR deletion prevents diastolic dysfunction in a preclinical HFpEF model, suggesting that the benefits of MR antagonists in HFpEF may be mediated by inhibiting fibroblast MR.
Absolute Event Rate: 0% vs 0%
Background: Heart failure with preserved ejection fraction (HFpEF) is a major health issue of our time. The pathophysiology of HFpEF is diverse, linked to comorbidities, such as kidney disease or obesity, and different from heart failure with reduced ejection fraction. As a consequence, treatment options are still limited. Recent clinical trials indicate beneficial effects of MR (mineralocorticoid receptor) antagonists in HFpEF, but the underlying mechanisms are incompletely understood. Methods and Results: We treated male and female mice with aldosterone and a high salt-diet to induce a preclinical cardiorenal HFpEF-like phenotype. Diastolic dysfunction and structural remodeling were comparable in both sexes and, of note, largely reversible after aldosterone withdrawal. Single-nucleus RNA sequencing of left ventricles indicated the greatest change in gene expression after aldosterone treatment in cardiomyocytes, endothelial cells, and fibroblasts. In response to aldosterone, we observed a shift towards a fibroblast subpopulation that is distinct from the canonical myofibroblast population typically seen in heart failure with reduced ejection fraction. Comparison with high-fat diet–induced HFpEF showed an overlapping upregulation of typical MR target genes in both models. To validate the functional consequence of this finding, we treated mice with fibroblast-specific MR deletion (MR TCF21Cre ). In contrast to a previous study in heart failure with reduced ejection fraction, MR deletion prevented the onset of diastolic dysfunction, suggesting different roles for fibroblast MR in heart failure subtypes. Conclusions: Diastolic dysfunction is associated with a fibroblast subtype that is different from the myofibroblasts observed in heart failure with reduced ejection fraction. MR activation is an overlapping feature of cardiorenal and cardiometabolic disease models. Further, MR deletion from fibroblasts prevents disease progression, suggesting that the beneficial effects of MR antagonists in HFpEF are related to inhibition of fibroblast MR.
Meral et al. (Wed,) reported a other. Mineralocorticoid receptor deletion in fibroblasts prevents diastolic dysfunction in preclinical models, indicating that MR antagonists benefit HFpEF by inhibiting fibroblast MR.